GSK hails progress for withdrawn blood cancer drug
UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...
pharmaphorum12d
GSK opens £10m AI hub in London
GlaxoSmithKline is opening a £10 million artificial intelligence (AI) research hub in King’s Cross, London, according to a press report. The area is being reimagined as a life sciences and ...
FTSE 100 Live 15 November: GDP disappoints, fresh GSK slump offsets Land Securities upgrade
The weaker backdrop means the FTSE 100 index is forecast to give up all yesterday’s rise, with futures pointing to a decline ...
FiercePharma6d
GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
STAT15d
Sales of GSK’s RSV vaccine down dramatically from last year
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
GlobalData on MSN8d
GSK CEO addresses declining trust in vaccines following Trump re-election
GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...
London's FTSE 100 falls as GSK warns on vaccine sales; UK budget in focus
The UK's benchmark FTSE 100 index fell on Wednesday, dragged by healthcare shares after GSK warned of lower annual vaccine ...
Bloomberg L.P.3d
GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...